Literature DB >> 16246030

Crystallographic and single-particle analyses of native- and nucleotide-bound forms of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

N H Awayn1, M F Rosenberg, A B Kamis, L A Aleksandrov, J R Riordan, R C Ford.   

Abstract

Cystic fibrosis, one of the major human inherited diseases, is caused by defects in the CFTR (cystic fibrosis transmembrane conductance regulator), a cell-membrane protein. CFTR acts as a chloride channel which can be opened by ATP. Low-resolution structural studies of purified recombinant human CFTR are described in the present paper. Localization of the C-terminal decahistidine tag in CFTR was achieved by Ni2+-nitriloacetate nanogold labelling, followed by electron microscopy and single-particle analysis. The presence of the gold label appears to improve the single-particle-alignment procedure. Projection structures of CFTR from two-dimensional crystals analysed by electron crystallography displayed two alternative conformational states in the presence of nucleotide and nanogold, but only one form of the protein was observed in the quiescent (nucleotide-free) state.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16246030     DOI: 10.1042/BST20050996

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  14 in total

1.  Cystic fibrosis transmembrane conductance regulator interacts with multiple immunoglobulin domains of filamin A.

Authors:  Martin P Playford; Elisa Nurminen; Olli T Pentikäinen; Sharon L Milgram; John H Hartwig; Thomas P Stossel; Fumihiko Nakamura
Journal:  J Biol Chem       Date:  2010-03-29       Impact factor: 5.157

2.  Functional and pharmacological induced structural changes of the cystic fibrosis transmembrane conductance regulator in the membrane solved using SAXS.

Authors:  Debora Baroni; Olga Zegarra-Moran; Oscar Moran
Journal:  Cell Mol Life Sci       Date:  2014-10-02       Impact factor: 9.261

3.  Small-angle X-ray scattering study of the ATP modulation of the structural features of the nucleotide binding domains of the CFTR in solution.

Authors:  Lauretta Galeno; Elena Galfrè; Oscar Moran
Journal:  Eur Biophys J       Date:  2011-03-22       Impact factor: 1.733

4.  ATP hydrolysis-dependent asymmetry of the conformation of CFTR channel pore.

Authors:  Oleg V Krasilnikov; Ravshan Z Sabirov; Yasunobu Okada
Journal:  J Physiol Sci       Date:  2011-04-03       Impact factor: 2.781

5.  Introduction to section IV: biophysical methods to approach CFTR structure.

Authors:  Juan L Mendoza; André Schmidt; Philip J Thomas
Journal:  Methods Mol Biol       Date:  2011

Review 6.  Dynamics intrinsic to cystic fibrosis transmembrane conductance regulator function and stability.

Authors:  P Andrew Chong; Pradeep Kota; Nikolay V Dokholyan; Julie D Forman-Kay
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

7.  NMR evidence for differential phosphorylation-dependent interactions in WT and DeltaF508 CFTR.

Authors:  Voula Kanelis; Rhea P Hudson; Patrick H Thibodeau; Philip J Thomas; Julie D Forman-Kay
Journal:  EMBO J       Date:  2009-11-19       Impact factor: 11.598

8.  Molecular models of the open and closed states of the whole human CFTR protein.

Authors:  Jean-Paul Mornon; Pierre Lehn; Isabelle Callebaut
Journal:  Cell Mol Life Sci       Date:  2009-08-26       Impact factor: 9.261

Review 9.  Cystic fibrosis transmembrane conductance regulator (ABCC7) structure.

Authors:  John F Hunt; Chi Wang; Robert C Ford
Journal:  Cold Spring Harb Perspect Med       Date:  2013-02-01       Impact factor: 6.915

10.  Three-dimensional reconstruction of human cystic fibrosis transmembrane conductance regulator chloride channel revealed an ellipsoidal structure with orifices beneath the putative transmembrane domain.

Authors:  Kazuhiro Mio; Toshihiko Ogura; Muneyo Mio; Hiroyasu Shimizu; Tzyh-Chang Hwang; Chikara Sato; Yoshiro Sohma
Journal:  J Biol Chem       Date:  2008-08-22       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.